中国抗体制药有限公司（股票代码：03681）于2026年2月4日发布截至2026年1月31日的股份变动月报表。公告显示，公司在报告期内未有新增发行、购回或注销股份，股本保持稳定。
根据公告，公司普通股于期末的已发行股份总数维持在1,386,638,336股，且无任何库存股份变动。报告期内亦无因股份期权行使而发行新股的情况。公司确认当前公众持股量已满足香港联交所的相关规定。
期权及激励方面，截至1月31日，购股权计划总数为69,009,462份，期内无新增或失效变动。其中16,926,100份可于期限内行使，未触发新股发行或库藏股转让。
公司同时声明，已遵守香港联交所《上市规则》及相关法律规定。本次公告由执行董事、主席兼首席执行官梁瑞安签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.